| ERCP术后急性胰腺炎药物预防临床研究现状 |
| |
| 引用本文： | 朱海杭,徐永居,张利. ERCP术后急性胰腺炎药物预防临床研究现状[J]. 国际消化病杂志, 2007, 27(6): 402-405 |
| |
| 作者姓名： | 朱海杭 徐永居 张利 |
| |
| 作者单位： | 江苏省苏北人民医院消化内科,扬州大学临床医学院,225001;江苏省苏北人民医院消化内科,扬州大学临床医学院,225001;江苏省苏北人民医院消化内科,扬州大学临床医学院,225001 |
| |
| 摘 要： | 逆行胰胆管造影术后急性胰腺炎(PEP)是逆行胰胆管造影最常见的并发症,发生率1%~40%。药物预防PEP临床研究已取得一定进展,生长抑素、加贝酯等有一定临床疗效,但许多药物临床效果不令人满意。
|
| 关 键 词： | 逆行胰胆管造影 并发症 逆行胰胆管造影术后胰腺炎 药物预防 |
| 修稿时间： | 2007-04-09 |
Review of pharmacological prevention of pancreatitis after ERCP |
| |
| ZHU Hai-hang,XU Yong-ju,ZHANG Li. Review of pharmacological prevention of pancreatitis after ERCP[J]. International Journal of Digestive Disease, 2007, 27(6): 402-405 |
| |
| Authors: | ZHU Hai-hang XU Yong-ju ZHANG Li |
| |
| Abstract: | Post-ERCP pancreatitis(PEP) represents the most common complication after ERCP. The reported incidence of this complication varies from 1% to 40%. Some attempts at preventing post-ERCP pancreatitis have been carried out using pharmacological prophylaxis. Several drugs are discussed in this review, only somatostatin and gabexate mesylate have consistently shown a moderate beneficial effect. The other results have been largely disappointing. |
| |
| Keywords: | ERCP Complication Post-ERCP pancreatitis Pharmacological prophylaxis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
